FDA committee rejects Solvay's tedisamil

An FDA expert panel has unanimously turned thumbs down on Solvay's tedisamil for atrial fibrillation. The experts said they would need more and better data before they could change their decision. Solvay says it will continue to work with regulators. The key problem, says the panel, is that the trial data indicates only a narrow dosage range that could be safe and effective. Serious side effects were noted for the high dosage and lower doses were less effective in treating the condition.

"It's almost like throwing a dart (to determine) what the dose should be," Tom Marciniak, medical team leader at FDA's cardiovascular and renal unit, told the advisory panel. "What will really happen to this drug when it's put out into the real world?"

- check out this release
- read the AFX report for more

ALSO: Solvay revealed a new family of biomaterials. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.